Log In Sign up
The largest database of trusted experimental protocols

Anti cd138 magnetic activated cell separation microbeads

Manufactured by Miltenyi Biotec
Visit Supplier
Sourced in Germany, United States

Anti-CD138 magnetic-activated cell separation microbeads are a laboratory tool used for the isolation and enrichment of cells expressing the CD138 (Syndecan-1) surface antigen. These microbeads can be used in magnetic-activated cell sorting (MACS) procedures to selectively separate target cells from complex samples.

Automatically generated - may contain errors

Lab products found in correlation

Ficoll paque plus, by GE Healthcare (6 mentions) Ficoll paque, by GE Healthcare (3 mentions) Easysep human b cell isolation kit, by STEMCELL (2 mentions) Human cd40 antibody, by R&D Systems (2 mentions) Recombinant human il 4, by R&D Systems (2 mentions) Histopaque 1077, by Merck Group (1 mentions) Ficoll paque, by Miltenyi Biotec (1 mentions) Ficoll hypaque, by Lonza (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Lonza (1 mentions) Anti human cd34 mabs, by Beckman Coulter (1 mentions) Ficoll hypaque, by Miltenyi Biotec (1 mentions) Anti cd38 antibody, by BD (1 mentions) Cd34 progenitor cell isolation kit, by Miltenyi Biotec (1 mentions)

17 protocols using anti cd138 magnetic activated cell separation microbeads

1

Isolation and Characterization of Multiple Myeloma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patient MM cells and bone marrow stromal cells (BMSCs) were obtained from BM samples after informed consent was obtained. All participants provided their written informed consent to participate in this study. This study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the Dana-Farber Cancer Institute. Mononuclear cells were separated using Ficoll-Hypaque density sedimentation, and plasma cells were purified (>95% CD138+) by positive selection with anti-CD138 magnetic-activated cell separation microbeads (Miltenyi Biotec, San Diego, CA, USA). Tumor cells were also purified from the BM of MM patients using the RosetteSep negative selection system (StemCell Technologies, Vancouver, BC, Canada). BMSCs were generated by culturing BM mononuclear cells for 4 to 6 weeks in DMEM supplemented with 15% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.
Suzuki R., Kikuchi S., Harada T., Mimura N., Minami J., Ohguchi H., Yoshida Y., Sagawa M., Gorgun G., Cirstea D., Cottini F., Jakubikova J., Tai Y.T., Chauhan D., Richardson P.G., Munshi N., Ando K., Utsugi T., Hideshima T, & Anderson K.C. (2015). Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE, 10(12), e0143847.
+ Open protocol
+ Expand
2

Isolation and Purification of Primary Plasma Cells and Bone Marrow Stromal Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs were obtained from blood samples from healthy volunteers by using Histopaque-1077 (Sigma-Aldrich) gradient fractionation. Bone marrow specimens were obtained from patients with MM after obtaining Sapporo Medical University School of Medicine Review Board approval and informed consent, and were obtained in compliance with the Declaration of Helsinki. Primary CD138+ plasma cells were purified by positive selection with anti-CD138 magnetic-activated cell separation microbeads (Miltenyi Biotec, Auburn, CA) as described [41 (link)]. According to a previous report, primary BMSCs were established from CD138− bone marrow mononuclear cells [35 (link)].
Kamihara Y., Takada K., Sato T., Kawano Y., Murase K., Arihara Y., Kikuchi S., Hayasaka N., Usami M., Iyama S., Miyanishi K., Sato Y., Kobune M, & Kato J. (2016). The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma. Oncotarget, 7(39), 64330-64341.
+ Open protocol
+ Expand
3

Isolation and Cultivation of Myeloma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow or peripheral blood samples were obtained from MM patients or healthy volunteers with informed consent and approval of the Institutional Review Board of the Dana-Farber Cancer Institute. After separating mononuclear cells from patients’ bone marrow by Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK), MM cells were purified by CD138-positive selection using anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Long-term MM patient BMSCs were established and maintained by culturing CD138-negative bone marrow mononuclear cells in DMEM containing 100U/m1 penicillin and 100μg/ml streptomycin, supplemented with 15% (v/v) fetal bovine serum (FBS). PBMNCs were isolated from normal donors’ peripheral blood using Ficoll-Paque centrifugation.
Ohguchi H., Harada T., Sagawa M., Kikuchi S., Tai Y.T., Richardson P.G., Hideshima T, & Anderson K.C. (2017). KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia, 31(12), 2661-2669.
+ Open protocol
+ Expand
4

Isolation of Primary MM Cells and BMSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
According to the Declaration of Helsinki, primary patient MM cells were obtained from bone marrow aspirates of MM patients with written informed consent. Mononuclear cells were separated using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Primary MM cells were further purified by CD138+ selection using anti-CD138 magnetic-activated cell separation microbeads (Miltenyi Biotec, San Diego, CA, USA). CD138− mononuclear cells were used to establish long-term BMSCs. All experiments with patient samples were performed according to a protocol approved by the Institutional Review Board of the Dana-Farber Cancer Institute.
de la Torre J.C, & Oldstone M.B. (1992). Selective disruption of growth hormone transcription machinery by viral infection.. Proceedings of the National Academy of Sciences of the United States of America, 89(20), 9939-9943.
+ Open protocol
+ Expand
5

Isolation of PBMC and Plasma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples collected from healthy volunteers were processed by Ficoll–Paque (GE Healthcare, Boston, MA, United States) gradient to obtain peripheral blood mononuclear cells (PBMCs). MM cells from individuals affected by MM were obtained from bone marrow samples after informed consent was obtained in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Dana–Farber Cancer Institute. Mononuclear cells were separated using Ficoll–Paque density sedimentation, and plasma cells were purified (>95% CD138+) by positive selection with anti–CD138 magnetic activated cell separation micro beads (Miltenyi Biotec, Cambridge, MA, United States).
Cottini F., Hideshima T., Suzuki R., Tai Y.T., Bianchini G., Richardson P.G., Anderson K.C, & Tonon G. (2015). Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer discovery, 5(9), 972-987.
+ Open protocol
+ Expand
6

Purification of Primary MM Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
According to the Declaration of Helsinki, primary patient MM cells were obtained from bone marrow aspirates of patients with MM with written informed consent. Mononuclear cells were separated using Ficoll–Paque PLUS (GE Healthcare Bio-Sciences). Primary MM cells were further purified by CD138+ selection using anti-CD138 magnetic-activated cell separation microbeads (Miltenyi Biotec). CD138− mononuclear cells were used to establish long-term BMSCs. All experiments with patient samples were performed according to a protocol approved by the Institutional Review Board of the Dana-Farber Cancer Institute.
Kurata K., Samur M.K., Liow P., Wen K., Yamamoto L., Liu J., Morelli E., Gulla A., Tai Y.T., Qi J., Hideshima T, & Anderson K.C. (2023). BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clinical Cancer Research, 29(9), 1807-1821.
+ Open protocol
+ Expand
7

Bone Marrow Samples from Multiple Myeloma Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow (BM) specimens were collected from 36 MM patients (18 males and 18 females; age range, 45–74 years) and 21 healthy donors (HDs) (10 males and 11 females; age range, 23–52 years) from the First Affiliated Hospital of Chongqing Medical University from September 2018 to November 2019. The patients’ details are listed in Table 1. Patients’ clinical information is provided as supplementary materials (see supplementary Table S1). Informed written consent was obtained from each MM patient and healthy donor, and the study protocol was approved by the Ethics Committee of Chongqing Medical University. The use of human samples complies with the standards stipulated in the Declaration of Helsinki. The Ethics Committee Approval is provided as Supporting Information. The study excluded patients undergoing radiotherapy, chemotherapy, immunoregulatory drugs, proteasome inhibitors, and autologous stem cell transplantation. Plasma cells from bone marrow were purified with anti‐CD138 magnetic‐activated cell separation microbeads (Miltenyi, Germany) according to the manufacturer's instructions, and the plasma cell purity was over 95%. The total RNA of the samples was extracted, reverse‐transcribed into cDNA, and stored at −80 °C until use.
Chen X., Li A., Zhan Q., Jing Z., Chen Y, & Chen J. (2020). microRNA‐637 promotes apoptosis and suppresses proliferation and autophagy in multiple myeloma cell lines via NUPR1. FEBS Open Bio, 11(2), 519-528.
+ Open protocol
+ Expand
8

Isolation of Myeloma Plasma Cells

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow aspirates were obtained from MM patients under approval of the Institutional Review Board of the Dana-Farber Cancer Institute. Mononuclear cells were isolated by density gradient centrifugation through Ficoll-Paque (GE Healthcare) and plasma cells were purified (>95% CD138+) by positive selection with anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotec, Auburn, CA, USA) (Mimura, et al 2014 (link)).
Yin L., Tagde A., Gali R., Tai Y.T., Hideshima T., Anderson K., Avigan D, & Kufe D. (2017). MUC1-C IS A TARGET IN LENALIDOMIDE RESISTANT MULTIPLE MYELOMA. British journal of haematology, 178(6), 914-926.
+ Open protocol
+ Expand
9

Isolation and Cultivation of Myeloma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow or peripheral blood samples were obtained from MM patients or healthy volunteers with informed consent and approval of the Institutional Review Board of the Dana-Farber Cancer Institute. After separating mononuclear cells from patients’ bone marrow by Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK), MM cells were purified by CD138-positive selection using anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Long-term MM patient BMSCs were established and maintained by culturing CD138-negative bone marrow mononuclear cells in DMEM containing 100U/m1 penicillin and 100μg/ml streptomycin, supplemented with 15% (v/v) fetal bovine serum (FBS). PBMNCs were isolated from normal donors’ peripheral blood using Ficoll-Paque centrifugation.
Ohguchi H., Harada T., Sagawa M., Kikuchi S., Tai Y.T., Richardson P.G., Hideshima T, & Anderson K.C. (2017). KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia, 31(12), 2661-2669.
+ Open protocol
+ Expand
10

Isolation and Stimulation of B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow or peripheral blood samples were obtained from MM patients or healthy donors with written informed consent after approval of the Institutional Review Board of the Dana-Farber Cancer Institute or Kumamoto University in accordance with Declaration of Helsinki. Mononuclear cells were isolated from samples by Ficoll-Paque PLUS (GE Healthcare). MM cells were enriched by anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotec). Normal B cells from healthy volunteers’ peripheral blood were enriched by negative selection methods using EasySep Human B Cell Isolation Kit (STEMCELL Technologies). For B cell proliferation, isolated B cells were stimulated by 10 μg/ml of human CD40 antibody (R&D systems) in the presence of 100U/ml of recombinant human IL-4 (R&D systems).
Ohguchi H., Park P.M., Wang T., Gryder B.E., Ogiya D., Kurata K., Zhang X., Li D., Pei C., Masuda T., Johansson C., Wimalasena V.K., Kim Y., Hino S., Usuki S., Kawano Y., Samur M.K., Tai Y.T., Munshi N.C., Matsuoka M., Ohtsuki S., Nakao M., Minami T., Lauberth S., Khan J., Oppermann U., Durbin A.D., Anderson K.C., Hideshima T, & Qi J. (2021). Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. Blood Cancer Discovery, 2(4), 370-387.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!